A 10-year $1.0 billion program to subsidize biotechnology and stem cell R&D in the US state of Massachusetts was close to final approval as the Marketletter was going to press. The State House of Representatives approved the package with support from a majority of both Democrats and Republicans, by 138 votes to 17 on June 11.
The State Senate was expected to endorse the legislation the following day and Governor Deval Patrick (Democrat) said he hopes to sign the proposal into law on June 16, before he attends the Biotechnology Industry Organization's International Convention in San Diego, California, the following day.
Gov Patrick will be accompanied by several leading political figures from the northeastern US state, as well as the president-elect of the Massachusetts Life Science Center, Susan Windham-Bannister. The Governor, who took office in January 2007 from Mitt Romney, the Republican who ran for President this year, was able to overcome any doubts that could have been caused by the perceived slow pace of a similar publicly-funded research scheme in California, (Marketletter March 3).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze